EUVIMEDEUVIMED entdecken
Crossref

Schisantherin A alleviates DSS-induced colitis by upregulating ferredoxin 1 to inhibit inflammation and restore intestinal barrier function

Hongyu Xiao, Na Li, Jiangyan Rao, Yuanling Zhang, Min Yu, Hua Yang

Phytomedicine · 2026

DOI: 10.1016/j.phymed.2026.158157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026. Verfasst von Hongyu Xiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Lignans, Cyclooctanes, Dioxoles, Colitis, Ulcerative. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Chongqing Municipality, Natural Science Foundation Project of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ulcerative colitis (UC) is a chronic non-specific inflammatory disease of the intestine with unknown etiology, and its effective treatments are still lacking. Repairing the intestinal mucosal barrier and reducing persistent inflammation is the key strategies for the treatment of UC. Schisantherin A (Sin A), a lignan compound extracted from Schisandra chinensis, exhibits anti-inflammatory, antioxidant, and neuroprotective effects. However, the role and mechanism of Sin A in the treatment of UC remains unclear. PURPOSE: This study aims to investigate the effect of Sin A on UC and elucidate its underlying molecular mechanism. METHODS: The effect of Sin A on UC was evaluated using a 3 % dextran sulfate sodium (DSS)-induced mouse model. Transcriptome sequencing analysis was performed to preliminarily explore the mechanism of Sin A in colitis. Based on the transcriptome results, the expression of proteins and mRNAs related to the FDX1-PI3K/AKT axis was determined by qPCR, immunofluorescence (IF), and western blotting. Additionally, plasmid transfection, molecular docking, drug affinity responsive target stability (DARTS), and cellular thermal shift assay (CETSA) were employed to verify the interaction between FDX1 and Sin A. RESULTS: Sin A can alleviate the clinical symptoms of UC mice, inhibit intestinal inflammation and repair intestinal barrier damage. Both transcriptomic sequencing results and ex vivo experiments confirmed that the therapeutic effect of Sin A on UC is associated with modulation of the FDX1-PI3K/AKT axis. Further studies demonstrated that FDX1 is a critical target for Sin A to inhibit the PI3K/AKT signaling pathway and exert its anti-UC effect. CONCLUSION: This study demonstrates for the first time that Sin A is a potential natural active ingredient for the treatment of UC, as it alleviates UC by suppressing inflammation and preventing barrier disruption. Furthermore, the critical role of the FDX1-PI3K/AKT axis in UC was confirmed, providing a theoretical basis for the application of Sin A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LignansCyclooctanesDioxolesColitis, UlcerativePolycyclic CompoundsColitisAnti-Inflammatory AgentsAnimalsDextran SulfateMiceUp-RegulationMaleMice, Inbred C57BLIntestinal Barrier FunctionInflammationDisease Models, AnimalSchisandraPhosphatidylinositol 3-KinasesIntestinal MucosaProto-Oncogene Proteins c-aktMolecular Docking SimulationSignal Transduction

Stichwörter der Autor:innen

Ferredoxin 1Intestinal barrierPI3K/AKT signaling pathwaySchisantherin AUlcerative colitis

Substanzen

LignansCyclooctanesDioxolesDextran SulfatePolycyclic CompoundsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktschizandrer AAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China.
  • Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China. Electronic address: yumimianbao@163.com.
  • Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China. Electronic address: hwbyang@126.com.

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Chongqing Municipality
  • Natural Science Foundation Project of Chongqing

Zitieren

APA

Xiao, H., Li, N., Rao, J., Zhang, Y., Yu, M., & Yang, H. (2026). Schisantherin A alleviates DSS-induced colitis by upregulating ferredoxin 1 to inhibit inflammation and restore intestinal barrier function. Phytomedicine. https://doi.org/10.1016/j.phymed.2026.158157

Vancouver

Xiao H, Li N, Rao J, Zhang Y, Yu M, Yang H. Schisantherin A alleviates DSS-induced colitis by upregulating ferredoxin 1 to inhibit inflammation and restore intestinal barrier function. Phytomedicine. 2026. doi:10.1016/j.phymed.2026.158157

BibTeX
@article{Xiao2026,
  author = {Xiao, Hongyu and Li, Na and Rao, Jiangyan and Zhang, Yuanling and Yu, Min and Yang, Hua},
  title = {Schisantherin A alleviates DSS-induced colitis by upregulating ferredoxin 1 to inhibit inflammation and restore intestinal barrier function},
  journal = {Phytomedicine},
  year = {2026},
  doi = {10.1016/j.phymed.2026.158157}
}
Kostenlos starten →